Introduction: Cardiovascular benefits and improved survival have resulted in statins becoming the most prescribed drugs in USA. There is a small but significant risk of developing statin induced rhabdomyolysis especially in combination with other lipid lowering medications for example fibrates like Gemfibrozil.
Case Presentation: We describe a case of an 82 year old male patient who developed rhabdomyolysis while taking a combination of Simvastatin and Gemfibrozil and was successfully managed with plasmapheresis.
Conclusion: There are only a few cases of rhabdomyolysis treated with plasmapheresis reported in literature. Most of the case reports of using this technique in rhabdomyolysis have been from Asia, Australia and Europe. We suggest that plasmapheresis may be considered as an option in severe life threatening rhabdomyolysis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769408 | PMC |
| http://dx.doi.org/10.4076/1757-1626-2-8138 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Kidney REPLACEment therapies in patients with acute kidney injury and RHABDOmyolysis (ReplaceRhabdo): a pilot trial.
BMC Nephrol
January 2025
Medical Department III, Division of Nephrology, University Hospital Leipzig, Leipzig, Germany.
Background: Rhabdomyolysis is frequently associated with acute kidney injury (AKI). Due to the nephrotoxic properties of myoglobin, its rapid removal is relevant. If kidney replacement therapy (KRT) is necessary for AKI, a procedure with effective myoglobin elimination should be preferred.
View Article and Find Full Text PDFHypokalemia-Induced Rhabdomyolysis Secondary to Adrenal Adenoma: A Case Report.
Cureus
December 2024
Pulmonary and Critical Care Medicine, Icahn School of Medicine at Mount Sinai/New York City Health + Hospitals - Queens, New York City, USA.
Adrenal adenoma, which leads to increased production of the hormone aldosterone, commonly presents as hypertension and hypokalemia. Rhabdomyolysis as a result of hypokalemia secondary to primary hyperaldosteronism is a rare but important complication with only a few reported cases. Low potassium levels can disrupt the regulation of arteriolar musculature, leading to reduced blood flow to skeletal muscles.
View Article and Find Full Text PDFLipid-Lowering Therapy Associated Erectile Dysfunction and Testicular Pain: A Rare Case Report.
Hosp Pharm
December 2024
Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysore, India.
Lipid-lowering therapy (LLT) includes a diverse group of pharmaceuticals designed to reduce blood levels of cholesterol and triglyceride (TG), helping to prevent cardiovascular diseases like myocardial infarction and stroke. LLT includes treatment with several lipid-lowering drugs (LLD), including hydroxymethylglutaryl (HMG-CoA) reductase inhibitors (statin), PCSK9 Inhibitors, cholesterol-absorbing inhibitors (Ezetimibe), Bile Acid Sequestrants, Fibrates, Niacin (Vitamin B3), Omega-3 Fatty Acids, Bempedoic Acid, and combination therapy. The efficacy and safety of these molecules vary widely.
View Article and Find Full Text PDFNon-oliguric acute renal failure secondary to a potentially lethal dose of caffeine with acute intoxication: a case report.
BMC Nephrol
December 2024
Kidney Disease and Transplant Center, Shonan Kamakura General Hospital, 1370-1 Okamoto, Kamakura, 247-8533, Kanagawa, Japan.
Background: Recently, the incidence of caffeine intoxication has been on an upward trend, with severe outcomes. However, acute kidney injury (AKI) resulting from renal pathologies secondary to caffeine intoxication is rare, and the pathophysiological mechanisms underlying AKI are unclear.
Case Presentation: A female patient in her 20s ingested an over-the-counter drug containing caffeine.
COL4A2-Related Disorder Presenting in Adulthood With Rhabdomyolysis.
Am J Med Genet A
December 2024
Department of Clinical Genomics, Mayo Clinic, Scottsdale, Arizona, USA.
The alpha 1 and 2 chains of type IV collagen, encoded by the COL4A1 (MIM 120130) and COL4A2 (MIM 120090) respectively, play essential roles in the vascular basement membranes. Pathogenic variants in COL4A1/ COL4A2 are associated with autosomal dominant cerebral angiopathies. The clinical manifestations of COL4A1/COL4A2-related disorders include: aneurysms, intracerebral hemorrhage, polymicrogyria, porencephaly, heterotopia, periventricular leukomalacia, epilepsy, and neurodevelopmental disorders.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!